Navigation Links
CLAAD Petitions FDA To Reject Opioid Medications Without Safety Features
Date:6/11/2013

WASHINGTON, June 11, 2013 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) joined in signing a Citizen Petition filed today urging the Food and Drug Administration (FDA) to fully implement the Obama administration's policy supporting a market transition to safer opioid medications. The petition asks that the FDA reject applications for new opioid medications without added safety features.

Opioids are a class of synthetically derived chemicals often used to treat pain or addiction. Opioid analgesics were involved in over 16,000 overdose deaths in 2010 alone, according to the Centers for Disease Control.

The petition praises the FDA's recent steps to shift the market to safer medications, such as the April conclusion that the original OxyContin pill was removed from the market for safety reasons. Copies of the non-abuse-deterrent formulation will not be approved because of this decision.

Recent FDA decisions regarding generic opioids cloud the future of abuse-deterrent medications. In May, the FDA ruled that manufacturers will be allowed to bring to market as early as July 1 more generic forms of a non-abuse deterrent version of Opana ER. The FDA is also expected to decide soon whether to approve an application for a new, pure hydrocodone pill with no abuse-deterrent features.

CLAAD's executive director, Michael Barnes, explained the need for action: "The availability of more generic, non-abuse-deterrent opioids increases the supply of drugs that people are eager and able to abuse. The better approach is to replace that supply with abuse-deterrent medications."

The citizen petition is asking that the FDA act speedily in accordance with the urgency of the national prescription abuse epidemic. By law, the FDA has 180 days to reply.

About the Center for Lawful Access and Abuse Deterrence
The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) coordinates a comprehensive national effort to prevent the prescription drug fraud, diversion, misuse, and abuse while advancing patient access to high-quality medical care. CLAAD enables health professionals, law enforcement, businesses, and government, and others, to share resources and work together to improve public health and safety.  Follow @claad_coalition.


'/>"/>
SOURCE CLAAD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CLAAD Warns of Increase in Prescription Drug Overdoses
2. CLAAD Names Eagle Advancement Institute as Honoree of Top 5 Technologies To Reduce Prescription Drug Abuse
3. CLAAD Highlights 5 Technologies To Reduce Prescription Drug Abuse
4. CLAAD Recognizes SMART/Script as Top 5 Technology To Reduce Rx Abuse
5. CLAAD Recognizes The Locking Cap as Top 5 Technology To Reduce Rx Abuse
6. CLAAD Selects Egalet As Top Five Technologies To Reduce Prescription Drug Abuse Honoree
7. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
8. TRICAST Debuts Part D Rejection Oversight Solution for Drug Plan Sponsors
9. Home Affairs Committees Drugs Report: Angelus Foundation Says the Prime Minister Should Not Have Rejected a Royal Commission
10. Express Scripts Recommends Rejection of TRC Capitals "Mini-Tender" Offer
11. New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... April 24, 2017 Solentim, the developer ... the addition of a major new product line ... Seeding,). The VIPS has been developed for automatically ... microplates as part of the process to generate ... simple and more reliable solution when compared to ...
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... 2017  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... that it will be participating in the Deutsche Bank ... Hotel in Boston, Massachusetts on ... 11:20 a.m. Eastern Time. A live webcast ... Investor Relations website at http://investor.zimmerbiomet.com .  The webcast ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... the way in unveiling cutting-edge birth defects research related to Zika virus during ... the world’s premier society for this important science. , The Teratology ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from medical ... heartened by the industry’s current surge. But another thing that unifies them is a ... last they can simply, safely and effectively end their aroma anguish thanks to a ...
(Date:4/25/2017)... ... 25, 2017 , ... Somnoware, a leading provider of digital ... module. Using this new feature, sleep physicians can now predict the likelihood of ... airway pressure (CPAP), oral, or other forms of sleep apnea therapy. The Somnoware ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
Breaking Medicine News(10 mins):